Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADAP
- CUSIP: N/A
- Web: www.adaptimmune.com
Average Prices:- 52 Week Range: $3.76 - $8.89
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.91
- P/E Growth: 0.00
Profitability:- Net Margins: -550.22%
- Return on Equity: -41.40%
- Return on Assets: -32.32%
Debt:- Current Ratio: 6.99%
- Quick Ratio: 6.99%
Misc:- Average Volume: 217,959 shs.
- Beta: 1.26
Frequently Asked Questions for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
What is Adaptimmune Therapeutics PLC's stock symbol?
Adaptimmune Therapeutics PLC trades on the NASDAQ under the ticker symbol "ADAP."
How were Adaptimmune Therapeutics PLC's earnings last quarter?
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.06. The firm had revenue of $2.86 million for the quarter, compared to analyst estimates of $5.07 million. Adaptimmune Therapeutics PLC had a negative net margin of 550.22% and a negative return on equity of 41.40%. View Adaptimmune Therapeutics PLC's Earnings History.
Where is Adaptimmune Therapeutics PLC's stock going? Where will Adaptimmune Therapeutics PLC's stock price be in 2017?
5 equities research analysts have issued twelve-month target prices for Adaptimmune Therapeutics PLC's shares. Their forecasts range from $15.00 to $16.00. On average, they anticipate Adaptimmune Therapeutics PLC's share price to reach $15.50 in the next twelve months. View Analyst Ratings for Adaptimmune Therapeutics PLC.
What are analysts saying about Adaptimmune Therapeutics PLC stock?
Here are some recent quotes from research analysts about Adaptimmune Therapeutics PLC stock:
- 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (7/17/2017)
- 2. Cowen and Company analysts commented, "Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells." (6/6/2017)
Who are some of Adaptimmune Therapeutics PLC's key competitors?
Some companies that are related to Adaptimmune Therapeutics PLC include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE) and China Biologic Products (CBPO).
Who are Adaptimmune Therapeutics PLC's key executives?
Adaptimmune Therapeutics PLC's management team includes the folowing people:
- James Julian Noble, Chief Executive Officer, Director
- Adrian Rawcliffe, Chief Financial Officer
- William C. Bertrand Jr., J.D., Chief Operating Officer
- Gwendolyn Binder-Scholl Ph.D., Chief Technology Officer
- William Roberts, Vice President of Investor Relations
- Rafael Amado M.D., Chief Medical Officer
- Helen Katrina Tayton-Martin Ph.D., Chief Business Officer
- David M. Mott, Non-Executive Chairman of the Board
- Lawrence M. Alleva, Non-Executive Independent Director
- Ali Behbahani M.D., Non-Executive Independent Director
When did Adaptimmune Therapeutics PLC IPO?
(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who owns Adaptimmune Therapeutics PLC stock?
Adaptimmune Therapeutics PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (12.86%) and Creative Planning (0.00%). Company insiders that own Adaptimmune Therapeutics PLC stock include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Institutional Ownership Trends for Adaptimmune Therapeutics PLC.
How do I buy Adaptimmune Therapeutics PLC stock?
Shares of Adaptimmune Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adaptimmune Therapeutics PLC's stock price today?
One share of Adaptimmune Therapeutics PLC stock can currently be purchased for approximately $5.35.
MarketBeat Community Rating for Adaptimmune Therapeutics PLC (NASDAQ ADAP)MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $15.50 (189.72% upside) |
Analysts' Ratings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/6/2017 | Cowen and Company | Reiterated Rating | Buy | | Low |  |
| 3/17/2017 | Wells Fargo & Company | Initiated Coverage | Market Perform -> Market Perform | | Low | |
| 11/11/2016 | Leerink Swann | Reiterated Rating | Buy | $15.00 | N/A | |
| 10/24/2016 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
| 9/30/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $16.00 | N/A | |
| 2/27/2016 | Deutsche Bank AG | Initiated Coverage | Buy | | N/A | |
| 2/25/2016 | Citigroup Inc. | Initiated Coverage | Buy | $15.00 | N/A | |
| 12/22/2015 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $16.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)Earnings History by Quarter for Adaptimmune Therapeutics PLC (NASDAQ ADAP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | 3/31/2017 | ($0.24) | ($0.30) | $5.07 million | $2.86 million | View | N/A | |
| 3/13/2017 | 12/31/2016 | ($0.27) | ($0.22) | $3.98 million | $8.54 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)2017 EPS Consensus Estimate: ($1.04)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.27) | ($0.24) | ($0.26) |
| Q2 2017 | 2 | ($0.26) | ($0.24) | ($0.25) |
| Q3 2017 | 2 | ($0.27) | ($0.25) | ($0.26) |
| Q4 2017 | 2 | ($0.29) | ($0.25) | ($0.27) |
(Data provided by Zacks Investment Research)
Dividend History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)Insider Ownership Percentage: 24.45%
Institutional Ownership Percentage: 56.16%
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/27/2017 | Enterprise Associates 14 New | Major Shareholder | Buy | 12,870,000 | $0.70 | $9,009,000.00 | |
| 3/27/2017 | Orbimed Advisors Llc | Director | Buy | 1,190,476 | $4.20 | $4,999,999.20 | |
| 5/24/2016 | Orbimed Advisors Llc | Director | Buy | 1,712,400 | $10.42 | $17,843,208.00 | |
| 5/19/2016 | Charles Elliott Sigal | Director | Buy | 15,000 | $1.56 | $23,400.00 | |
| 5/18/2016 | Charles Elliott Sigal | Director | Buy | 45,000 | $1.53 | $68,850.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Latest Headlines for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| Source: |
|
Adaptimmune Therapeutics PLC (ADAP) Chart for Thursday, July, 27, 2017
